10 results about "Acute diarrhea" patented technology

The invention discloses an antibody for detecting porcine acute diarrhea syndrome coronavirus, a fluorescence immunochromatography test strip and application of the antibody and the fluorescence immunochromatography test strip, and aims to overcome the defects that an existing SADS-CoV detection technology is low in sensitivity, complex to operate and incapable of being applied on site. The method comprises the following steps: screening high-specificity anti-S1 protein monoclonal antibodies (such as 1B8 and 3C9); a quantum dot labeled antibody is combined with a chromatographic structure containing a T line (S1 protein) and a C line (SPA protein); the kit provided by the invention has the advantages that by optimizing the formula of the buffer solution, the technical effects of high-sensitivity detection (100 TCID50 / mL), on-site rapid visual interpretation and zero cross reaction are realized, the technical bottleneck of on-site rapid and accurate diagnosis is overcome, the operation is simple and convenient, and the kit is suitable for on-site screening of clinical samples.

The invention discloses a multiplex nucleic acid detection kit for swine acute diarrhea pathogens and application of the multiplex nucleic acid detection kit. The kit comprises an RAA (Reverse Amplification) primer pair, a specific crRNA (Ribonucleic Acid), a Cas12a protein, an NEBbuffer r2.1 and an ssDNA (Deoxyribose Nucleic Acid) reporter molecule, wherein the RAA primer pair, the specific crRNA, the Cas12a protein, the NEBbuffer r2.1 and the ssDNA reporter molecule are used for detecting the porcine epidemic diarrhea virus (PEDV), the porcine rotavirus (PoRV) and the porcine sapelovirus (PSV). According to the method, reverse transcription, amplification and Cas12a detection processes are coupled through an integrated system or a continuous reaction mode, the whole process is completed under the condition of constant temperature (37 DEG C), thermal cycle equipment is not needed, and only a constant-temperature heating device is needed. After the reaction is finished, a result can be observed through a portable blue light detector or naked eyes, so that on-site real-time visual interpretation is realized.

The invention belongs to the technical field of biological medicines, and provides an S protein ancestor sequence AS mRNA of a porcine acute diarrhea syndrome coronavirus, the ancestor sequence of an SADS-CoV Spike protein is constructed through phylogenetic analysis, and the sequence aims at the existing virus and also aims at the evolution pedigree of the virus; the sequence design is used for converting target defense aiming at a single pathogen into active intervention on a virus evolution trajectory; and the prepared AS mRNA vaccine has important significance on feeding safety of animals and prevention and control of zoonosis diseases.

The present application belongs to the technical field of biological industry, and particularly relates to a spike protein antigen epitope peptide of porcine acute diarrhea syndrome coronavirus, a monoclonal antibody thereof and application. The present application provides an antibody or an antigen binding fragment thereof, a nucleotide sequence of a heavy chain variable region of the antibody or the antigen binding fragment thereof is shown as SEQ ID NO. 2; a nucleotide sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO. 4. A minimum binding epitope amino acid sequence is shown as SEQ ID NO. 22, and the antigen epitope is highly conserved in various different subtypes of SADS-CoV. The antibody can be applied to basic research on a SADS-CoV invasion molecular mechanism, and provides good scientific research materials for application research of SADS-CoV detection and treatment.

The invention discloses a porcine acute diarrhea syndrome coronavirus capsid protein monoclonal antibody and application thereof, and belongs to the technical field of biology. According to the invention, capsid protein of porcine acute diarrhea syndrome coronavirus SADS-CoV is taken as a detection marker, recombinant capsid protein of SADS-CoV is expressed through an eukaryotic expression system, a monoclonal antibody of anti-capsid protein is prepared by using a hybridoma technology, and then the SADS-CoV colloidal gold rapid diagnosis test strip is prepared by using the monoclonal antibody and a colloidal gold test strip evaluation system. The porcine acute diarrhea syndrome coronavirus capsid protein monoclonal antibody provided by the invention is used for preparing an immunochromatography detection test strip, can be used for rapidly detecting porcine acute diarrhea syndrome coronavirus, and is simple, convenient, easy in result judgment and suitable for field.

The application belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant pig acute diarrhea syndrome coronavirus vaccine. The application constructs a replication-defective adenovirus vector vaccine (rAd-SADS-S) expressing a full-length SADS-CoV S protein, realizes immune induction of high-efficiency humoral and cellular immunity, and provides passive protection for milk mice through maternal antibody transmission, and overcomes the defects of no available vaccine for SADS-CoV, low protection rate in existing research, and biological safety risk.

The invention discloses a primer group for simultaneously detecting porcine acute diarrhea syndrome coronavirus and bat HKU2 coronavirus, and belongs to the technical field of biology. The primer combination disclosed by the invention can be used for simultaneously detecting the porcine acute diarrhea syndrome coronavirus (SADS-CoV) and the bat HKU2 coronavirus, and the lowest limit of detection (LOD) is 20 copies per reaction; the primer provided by the invention is combined with three gene conserved regions of SADS-CoV and HKU2 coronavirus, and has relatively high specificity. The method has high reference value for nucleic acid diagnosis of SADS-CoV and HKU2 coronavirus, and is suitable for popularization and application.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for improving intestinal dysfunction and a preparation method and application thereof. The composition is prepared from the following raw materials in parts by weight: 18 to 25 parts of collagen peptide, 14 to 20 parts of yeast polypeptide, 10 to 16 parts of betaine, 7 to 15 parts of emblic leafflower fruit extract, 6 to 12 parts of olive extract, 9 to 14 parts of xylooligosaccharide and 3 to 5 parts of yeast beta-glucan. The amino acid sequence of the collagen peptide is as shown in SEQ ID NO. 1. By taking the composition prepared by the invention, acute diarrhea and constipation can be quickly relieved, intestinal inflammation can be improved, and the composition can enduringly act on the internal environment of intestinal tracts, so that deep and enduringly improvement of intestinal dysfunction is realized, and the composition has a wide application prospect.

The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.

This invention utilizes an insect-baculovirus expression system to prepare the recombinant protein SADS-CoV-S of porcine acute diarrhea syndrome coronavirus, which is then used to prepare egg yolk antibodies. By optimizing the composition of the subunit vaccine composition for immunizing laying hens, IL-2 and ZnCl2 solution are added as immunostimulants to the conventional adjuvant, increasing the antibody concentration in the egg yolk antibody extract and improving the neutralizing antibody titer and protective efficacy. When IL-2 and zinc chloride aqueous solution are added to the immunization composition simultaneously, the resulting egg yolk antibody aqueous solution exhibits the highest protein concentration, and at the same protein concentration, the egg yolk antibody has the highest neutralizing titer. Compared to the immunization composition using Freund's complete adjuvant alone, the neutralizing titer is increased by more than 60 times.